Caifeng Fu
PAREXEL International (United States) · 15 works · 5,073 citations · h-index 9
Top works
- RAGE Mediates a Novel Proinflammatory Axis
- Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases
- N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression
- Advanced Glycation End Products Activate Endothelium Through Signal-Transduction Receptor RAGE
- Expression of Advanced Glycation End Products and Their Cellular Receptor RAGE in Diabetic Nephropathy and Nondiabetic Renal Disease
- Pharmacodynamics and Safety of Pantoprazole in Neonates, Preterm Infants, and Infants Aged 1 Through 11 Months with a Clinical Diagnosis of Gastroesophageal Reflux Disease
- A Phase I Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Adults With Severe Renal Impairment and Healthy Matched Control Participants
- Newborn screening for primary carnitine deficiency in Quanzhou, China
- Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection
- Pharmacokinetics of Two Dose Levels of Pantoprazole Sodium Delayed-Release Granules for Oral Suspension in Infants Aged 1 Through 11 Months with a Presumed Diagnosis of GERD
- Bioequivalence and Food Effect Assessment of 2 Fixed‐Dose Combination Formulations of Dolutegravir and Lamivudine
- M1908 Pharmacodynamics (PD) and Safety of Pantoprazole Delayed-Release Granules in Infants Aged 1 Through 11 Months with a Clinical Diagnosis of Gastroesophageal Reflux Disease (GERD)
- Pharmacokinetics of Cabotegravir in Subjects with Severe Renal Impairment
- The Effect of Moderate- and High-Fat Meals on the Bioavailability of Dolutegravir/Rilpivirine Fixed-Dose Combination Tablet
- Cabotegravir(CAB) Safety Meta-analysis Update from 14 Phase I/IIa Studies